Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03414203
Other study ID # NEUROMIG
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 14, 2017
Est. completion date February 16, 2018

Study information

Verified date August 2019
Source Federal University of Paraíba
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to compare the effects of transcranial direct current stimulation on the clinical and cognitive function in patients with chronic migraine.


Description:

The patients will be randomized into 1 of 3 groups: active tDCS for 15 minutes, active tDCS for 15 minutes, with an interval of 20 minutes and more 15 minutes os stimulation, sham tDCS for 15 minutes. The tDCS will be applied for 10 days over 2 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date February 16, 2018
Est. primary completion date February 5, 2018
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria:

- females

- clinical diagnosis of chronic migraine according to the International Classification of Headaches Disorders (ICHD-3 beta).

Exclusion Criteria:

- headache attributable to some pathological condition, associated neurologic or neuropsychiatric disease

- use of central nervous system modulating drugs

- pregnancy

- metallic head implants

- use of a cardiac pacemaker

Study Design


Related Conditions & MeSH terms


Intervention

Other:
tDCS
Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.

Locations

Country Name City State
Brazil Federal University of Paraiba João Pessoa Paraiba

Sponsors (1)

Lead Sponsor Collaborator
Federal University of Paraíba

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Migraine Disability Assessment - MIDAS Change in perform activities of daily living associate to migraine assessed on the Migraine Disability Assessment - MIDAS. "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Headache Impact Test - HIT-6 Change in quality of life associate to migraine assessed on the Headache Impact Test-6 (HIT-6) "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Wechsler Intelligence Scale Letters Change in cognitive ability assessed on the Wechsler Adult Intelligence Scale Letters "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Wechsler Intelligence Scale Numbers Test Change in cognitive ability assessed on the Wechsler Adult Intelligence Scale Numbers Test "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Hayling's Test Hayling's Test Change in operational memory assessed on the Hayling's Test Evaluate operational memory "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Trail Making Test part B Change in executive functions assessed on the Trail Making Test part B "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Salthouse Visual Patterns and Lyrics Change in visual processing speed assessed on the Salthouse Visual Patterns and Lyrics "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Nine Hole Peg Test Change in the motor processing speed assessed on the Nine Hole Peg Test "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Paced Auditory Serial Addition Task Change in selective attention assessed on the Paced Auditory Serial Addition Task "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Concentrated Attention Test Change in selective attention assessed on the Concentrated Attention Test "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Visual Attention Test (Attention Matrices) Change in selective attention assessed on the Visual Attention Test (Attention Matrices) "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Montreal Cognitive Assessment Change in cognition assessed on the Montreal Cognitive Assessment "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Secondary Side Effects Questionnaire adverse effects assessment "every day for up to 2 weeks"
See also
  Status Clinical Trial Phase
Completed NCT05720819 - Biofeedback-VR for Treatment of Chronic Migraine N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Completed NCT02514148 - Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients N/A
Enrolling by invitation NCT02291380 - A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic Migraine Phase 3
Completed NCT02122237 - Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial Phase 3
Withdrawn NCT02122744 - RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine N/A
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT01709708 - Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine Phase 4
Completed NCT01741246 - Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging N/A
Completed NCT01090050 - Treximet in the Treatment of Chronic Migraine Phase 4
Recruiting NCT03507400 - Introvision for Migraine and Headaches N/A
Completed NCT04161807 - Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine N/A
Completed NCT03175263 - OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain N/A
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT01667250 - Non-Invasive Neurostimulation for the Prevention of Chronic Migraine N/A
Completed NCT01700387 - A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency Phase 4
Not yet recruiting NCT01135784 - Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache Phase 2
Completed NCT00772031 - NINDS CRC Chronic Migraine Treatment Trial Phase 3